Argenx
Manufacturing · Netherlands · 1K - 5K Employees
View Company Info for Free
Overview
Headquarters
Laarderhoogtweg 25, Amsterdam, North Hol...Phone Number
+31 107038441Website
www.argenx.comRevenue
$2.6 BillionStock Symbol
ARGXIndustry
ZI Rank: 1
Signal Type
Jan
Feb
Mar
Apr
May
Jun
ZI Rank
5
1
2
1
1
1
About Argenx
At argenx, we build our culture from the collective power of the team and the knowledge that together, we are better. We are all co-owners of this company; we recognize that each individual performance contributes to the broader purpose. We align the personal growth of our employees with the shared goals of the organization.Explore more
Argenx Org Chart
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is Argenx your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Argenx, which may be a good buyer, showed buying intent in Masked Content Topic
Product Launch: Get notified when Argenx launches new products
Congratulate Masked Content for being promoted to Masked Content at Argenx
Check out if Argenx is spiking on competitors!
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Check if Argenx has recently received funding, and reach out quickly before it becomes old news!
Earning: See what the market has to say on Argenx recently announced quarterly report
Funding: Get notified immidiatlly once Argenx has new funding data
Website visits: Recent activity has been detected on your website
Click to see if Argenx had a recent Job posting/layoffs
Recommended Actions
Introduce yourself to Masked Content, who has shown a strong intent to purchase lately
Find more new buyers
Company Profile Activity
Activity Insights
Argenx is experiencing very low activity levels compared to other companies in the Manufacturing sector.
What does this means?
Argenx is drawing exceptional interest within the Manufacturing industry, suggesting notable developments or strong market momentum, learn more about Argenx.
Argenx financials insights
Gather financial insights about Argenx, including details on funding rounds, investors, total funding, and acquisitions, to gain a comprehensive understanding of their financial strategy.
2014
Stock Offering
$54.4M
2017
Stock Offering
$100M
2020
Stock Offering
$750M
Argenx Tech Stack
A closer look at the technologies used by Argenx
See more technologies
Most Recent Scoops
Open Position
Project
Argenx has disclosed its commercial readiness for a potential autoimmune myositis launch, including patient support programs, more than 90% US payer coverage already in place for VYVGART, an expanded MSL team engaged with 650 autoimmune myositis key opinion leaders across neurology, dermatology, and rheumatology, a disease education campaign already launched, patient advocacy group engagement ongoing for more than two years, and planned sales force expansion into rheumatology and dermatology upon positive data, with argenx ranked first among MSLs by autoimmune myositis KOLs in market research.
CRM, Partnership, Digital Marketing, Product Marketing, Advertising, Product Development, User Experience, Analytics & Insights, Product Launch, Media / Creative Agency, Clinical Systems, Training, Branding, Content Management, Customer Engagement, Marketing Campaign, Product Management, Sales, Social Media, User Interface, Learning & Development, Business Development, Demand Generation, Lead Management, Sales Development, Software, Customer Service, Customer Marketing, Event Marketing, Relationship Marketing, Strategic Communications, Technical Marketing, Medical Education & Training, Medical Research, Pharmaceuticals, Consumer Technology, Account Management, Field /Outside Sales, Inside Sales, Accessibility, Channel Sales, Communications, Content Marketing, Contracts, Customer Experience, Customer Retention & Development, Customer Success, Design & Graphics, Event Management, Healthcare Technology, Lead Generation, Marketing Analytics / Insights, Marketing Communications, Marketing Operations, Marketing Strategy, Marketing Technology, Pricing, Public Relations, Sales Enablement, Sales Operations, Sales Technology, Sales Training, Social Media Marketing
Project
Argenx has reported that blinded market research conducted in Q1 showed nine out of ten rheumatologists indicated they would use VYVGART to treat IMNM if approved, with the core unmet need identified as rapid onset of efficacy and systemic muscle efficacy in a disease where no treatments are currently approved.
Medical Research
Project
Argenx has reported preclinical evidence supporting efgartigimod in autoimmune myositis from two models: an IMNM mouse model in which treatment with efgartigimod reduced muscle necrosis, increased muscle regeneration, and restored grip strength after disease establishment, and an antisynthetase syndrome model in which an efgartigimod mouse analog clearly improved lung fibrosis and restored normal lung architecture.
Project
Product Development, Pharmaceuticals
Argenx News & Media
argenx to Present at BofA Securities 2026 Health Care Conference
May 6, 2026 Amsterdam, the Netherlands – argenx (Euronext & Nasdaq: ARGX), a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases, today announced that Karen Massey, Chief Executive Officer, will present at the BofA Securities 2026 Health Care Conference on Tuesday, May 12, 2026 at 10:40 a.m. PT.Here’s Why Argenx SE (ARGX) Slipped in Q1
Baron Capital, an investment management company, released its Q1 2026 investor letter for the “Baron Health Care Fund”. A copy of the letter is available to download here. Baron Health Care Fund (the Fund) declined 6.97% (Institutional Shares) in the quarter, compared to the 4.88% decline for the Russell 3000 Health Care Index (the Benchmark) and […]Analysts Highlight Vyvgart Expansion as Major Growth Driver for Argenx (ARGX)
Argenx SE (NASDAQ:ARGX) ranks among the best growth stocks to buy and hold for the long term. Following the company’s Q4 results, Oppenheimer increased its price target for Argenx SE (NASDAQ:ARGX) to $1,060 from $1,040 on February 26 while keeping an Outperform rating. The company reported earnings per share of $8.02, exceeding the projected $5.95. […]Argenx (ARGX) 2025 Net Product Sales Rise 90% to $4.2B as First Annual Profit Reached
Argenx SE (NASDAQ:ARGX) is one of the best NASDAQ stocks to buy according to hedge funds. On February 26, Argenx reported earnings for 2025, achieving its first year of annual operating profitability with $4.2 billion in net product sales, a 90% increase over 2024. This growth was fueled by the global adoption of VYVGART, which […]
Read more news
Top Manufacturing Companies
Top companies in Canada by revenue
Top companies in Australia by revenue
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding Argenx
Sign Up For FreeTo access detailed company insights
At argenx, we build our culture from the collective power of the team and the knowledge that together, we are better. We are all co-owners of this company; we recognize that each individual performance contributes to the broader purpose. We align the personal growth of our employees with the shared goals of the organization.... Read More
